Zentalis Pharmaceuticals Inc（ZNTL）财务数据ZNTLZentalis Pharmaceuticals Inc

Evaluating the bottom line, Zentalis Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -66.75%, provide a clear picture of how effectively ZNTL converts its operational activities into shareholder value.

In the context of the broader market, ZNTL competes directly with industry leaders such as FHTX and LYEL. With a market capitalization of $255.15M, it holds a significant position in the sector. When comparing efficiency, ZNTL's gross margin of N/A stands against FHTX's 100.00% and LYEL's 100.00%. Such benchmarking helps identify whether Zentalis Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Zentalis Pharmaceuticals has shown significant volatility with a YTD change of +177.37% and a 1-year change of +120.93%. However, the company has reported consistent net losses, with the latest net income of -$42.29 million in Q2 2026. The gross margin is currently at 100% for Q4 2024, but there are no revenues in subsequent quarters, indicating a lack of sales.